Please select the option that best describes you:
Topics:
Radiation Oncology • Genitourinary Cancers
Is treating high-risk prostate cancer with trimodality therapy safe for a patient who remains on anti-PD1 therapy for metastatic melanoma?
If the patient is in remission for metastatic melanoma but continue to take an anit-PD1 therapy, it giving ADT, EBRT + brachytherapy safe for a high risk prostate cancer?
Answer from: Radiation Oncologist at Community Practice
More important question is do we need to treat patient with triple modality for high risk disease if they have metastatic melanoma as outcome would be dictated by metastatic disease
Sign in or Register to read more